Insufficient control of blood pressure (BP) in hypertension continues to represent an unmet need of contemporary medicine. In a recent analysis performed by the NCD-RisC (non-communicable diseases Risk Factor Collaboration), BP control ranged from about 15% to 60%.1 In addition, a cross-sectional analysis of National Health and Nutrition Examination Survey showed that the proportion of patients with controlled BP has even declined to 43.7% in the most recent timeframe (2017–2018).
Novel ANP (Atrial Natriuretic Peptide) based therapy for hypertension: the promising role of a disease mechanism targeted approach / Volpe, Massimo; Gallo, Giovanna; Rubattu, Speranza. - In: HYPERTENSION. - ISSN 0194-911X. - 78:6(2021), pp. 1868-1870. [10.1161/HYPERTENSIONAHA.121.18264]
Novel ANP (Atrial Natriuretic Peptide) based therapy for hypertension: the promising role of a disease mechanism targeted approach
Volpe, Massimo
Conceptualization
;Gallo, GiovannaInvestigation
;Rubattu, SperanzaConceptualization
2021
Abstract
Insufficient control of blood pressure (BP) in hypertension continues to represent an unmet need of contemporary medicine. In a recent analysis performed by the NCD-RisC (non-communicable diseases Risk Factor Collaboration), BP control ranged from about 15% to 60%.1 In addition, a cross-sectional analysis of National Health and Nutrition Examination Survey showed that the proportion of patients with controlled BP has even declined to 43.7% in the most recent timeframe (2017–2018).| File | Dimensione | Formato | |
|---|---|---|---|
|
Volpe_Novel-ANP_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
222.58 kB
Formato
Adobe PDF
|
222.58 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
